Barasertib (AZD1152-HQPA) 化学構造
分子量: 507.56

高品質保証

カスタマーフィードバック(8)

Quality Control & MSDS

製品説明

  • Compare Aurora Kinase Inhibitors
    Aurora Kinase製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Barasertib (AZD1152-HQPA)は、0.37nMのIC50による非常に選択的なオーロラB阻害剤です。
ターゲット Aurora B
IC50 0.37 nM [1]
In vitro試験 AZD1152 displays >3000-fold selectivity for Aurora B as compared with Aurora A which has an IC50 of 1.368 μM. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells with IC50 of 3-40 nM, displaying ~100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 μM. AZD1152 inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, as well as the freshly isolated imatinib-resistant leukemia cells with IC50 values of 1-3 nM, more significantly compared with bone marrow mononuclear cells with IC50 values of >10 nM. AZD1152 induces accumulation of cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
LNCaP M2XEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlGyNE02ODBibl2= NEjVN2E1QMLiaB?= MkjDTWM2OD1{NTDuUS=> MoDYNlUzPzd4NUm=
LNCaP MYLBdI9xfG:|aYOgRZN{[Xl? MWmwMVUxOCCwTR?= MlXEOFjDqGh? M2H3SIlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIghfGi{b4XnbEBk[XOyYYPlMVMhfXC{ZXf1cIF1cW:w NWrEUmNkOjV{N{e2OVk>
LNCaP M3K0RWZ2dmO2aX;uJGF{e2G7 NIrlWVc2OCCwTR?= NVr0dZk{PDhiaB?= NYfy[pJqcW6mdXPld{BucWO{b371Z4xmcSC5aYToJIFv\XWpZX7pZ{Bu\WOqYX7pd40> M2Wze|I2Ojd5NkW5
Ramos M4HCZ2Z2dmO2aX;uJGF{e2G7 MYW1NFAhdk1? Mln5NE04OiCq NGPTTppqdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= NH7nd|czOTN5MUS0Oi=>
Daudi  NVH6W2JqTnWwY4Tpc44hSXO|YYm= NUjJNXNjPTByIH7N MYmwMVczKGh? MnvzbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn MkjlNlE{PzF2NE[=
L540 NFvXbW5HfW6ldHnvckBCe3OjeR?= NEfnV242ODBibl2= MoO3NE04OiCq NIrZWoFqdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= NYHjd|FFOjF|N{G0OFY>
BJAJ NETUVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\0OVAxKG6P NFjhUIcxNTd{IHi= Mle5bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NWTVRVJYOjF|N{G0OFY>
Ramos NYKzTW1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P1Z|UxOCCwTR?= NGLM[GQxNTd{IHi= NXv3RnlWcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> Mk\TNlE{PzF2NE[=
Raji Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu1NFAhdk1? MmPpNE04OiCq NV3jT|NkcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> M1\HOlIyOzdzNES2
Daudi  NXPvPJV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[3fJc2ODBibl2= NGraPXgxNTd{IHi= MorzbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NULQVZlVOjF|N{G0OFY>
L428 M3TLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TwdFUxOCCwTR?= MnrmNE04OiCq MXTpcohq[mm2czDj[YxtKGe{b4f0bC=> M3rjUFIyOzdzNES2
KM-H2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S3[|UxOCCwTR?= MmnUNE04OiCq M3PUdIlvcGmkaYTzJINmdGxiZ4Lve5Rp Mn3sNlE{PzF2NE[=
HDLM-2 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[1NFAhdk1? M{T1SFAuPzJiaB?= MYnpcohq[mm2czDj[YxtKGe{b4f0bC=> MWiyNVM4OTR2Nh?=
L450 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO1NFAhdk1? MmnwNE04OiCq NVTGelJZcW6qaXLpeJMh[2WubDDndo94fGh? M4TZO|IyOzdzNES2
BJAJ MV3BdI9xfG:|aYOgRZN{[Xl? NYT1dW9IPTByIH7N MkjkNE04OiCq M{ntR4lv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHXTVY4zOTN5MUS0Oi=>
Ramos NE\RcmlCeG:ydH;zbZMhSXO|YYm= MnKwOVAxKG6P M{C1O|AuPzJiaB?= NGPyWG1qdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MWCyNVM4OTR2Nh?=
Raji MYPBdI9xfG:|aYOgRZN{[Xl? NVrKcYVzPTByIH7N NFvNfWQxNTd{IHi= NVfuU2ZYcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M13XcFIyOzdzNES2
Daudi  MXzBdI9xfG:|aYOgRZN{[Xl? MV21NFAhdk1? MXSwMVczKGh? NYXnWIlycW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MXiyNVM4OTR2Nh?=
L428 NIrBfZFCeG:ydH;zbZMhSXO|YYm= NH[4enQ2ODBibl2= MUOwMVczKGh? MYXpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NWj6cpRtOjF|N{G0OFY>
KM-H2 MYXBdI9xfG:|aYOgRZN{[Xl? NWi4d2kxPTByIH7N M1i0WFAuPzJiaB?= NVHVSZRZcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MUeyNVM4OTR2Nh?=
HDLM-2 NHO3fppCeG:ydH;zbZMhSXO|YYm= NYX3bnhVPTByIH7N NEDmclUxNTd{IHi= NH7JS29qdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MV[yNVM4OTR2Nh?=
L450 NHr1OYtCeG:ydH;zbZMhSXO|YYm= MUC1NFAhdk1? Mkm5NE04OiCq Mnq2bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MWWyNVM4OTR2Nh?=
SW620 NFTpeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Th[GVEPTB;MUFCtVIvOSCwTR?= M4fn[FIyOjR3MEmw
HCT116 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLvTIJpTUN3ME2xNeKyOy5|IH7N MUWyNVI1PTB7MB?=
MDA-MB-435 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDYZopEOC1zMECwNEBvVQ>? NUnmV5dKOi13IHS= NG\scmZFVVOR NUXiPFE1UUN3ME2xNlUhdk1? MVqyNFE4PTl{Nh?=
MDA-MB-468 NFXWS5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HTZ|AuOTByMECgcm0> NGnDcIYzNTViZB?= M{[1fmROW09? NFvkVmhKSzVyPUG0JI5O NFXQbFUzODF5NUmyOi=>
MDA-MB-231 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXEbJgxNTFyMECwJI5O NEjRZpIzNTViZB?= M33IUmROW09? MWDJR|UxRTFyNTDuUS=> M3XvUlIxOTd3OUK2
BT474 M4Hucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfINE0yODByMDDuUS=> MnfCNk02KGR? MV\EUXNQ MUnJR|UxRThibl2= NG\JNmMzODF5NUmyOi=>
MDA-MB-361 NFvGN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPUSZAxNTFyMECwJI5O MmLuNk02KGR? NWT5ZYZYTE2VTx?= MYHJR|UxRTdyIH7N MmfnNlAyPzV7Mk[=
HER18 NXzTdpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\mXG13OC1zMECwNEBvVQ>? M3rOc|IuPSCm NGLmZmRFVVOR NWTYSGVFUUN3ME2yNEBvVQ>? MkPHNlAyPzV7Mk[=
HER18 NYXGV414SXCxcITvd4l{KEG|c3H5 Ml7VNVAxKG6P NF\Xcm0xNzJ2L{S4JIg> NXfQ[4dMTE2VTx?= Mmr5bY5lfWOnczDhdI9xfG:|aYOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yCyb4TlcpRq[Wx? MWWyNFE4PTl{Nh?=
MDA-MB-231 MVfBdI9xfG:|aYOgRZN{[Xl? MUmxNFUhdk1? NHjHZY0xNzJ2L{S4JIg> M3TLV2ROW09? Mn[4bY5lfWOnczDhdI9xfG:|aYOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yCyb4TlcpRq[Wx? M4\VTlIxOTd3OUK2
JHH-1 NHvtV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e5TFAvO+LCk{GwNFDDqG6P M2rVZVczKGh? MoPZSWM2OD1zNz60xtEyNjBibl2= M3fFR|E6QTF|OUO1
JHH-2 M2mzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKwMlPjiJNzMECwxsBvVQ>? NX\BNmEyPzJiaB?= MWPFR|UxRTJzOD6wxtEyOC56IH7N NUjxTJc2OTl7MUO5N|U>
JHH-4 NW\kPGZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrnVHJVOC5|4pETNVAxOMLibl2= MkD5O|IhcA>? NV;nd21WTUN3ME2xOVUvPsLzMU[uPEBvVQ>? NHKydXcyQTlzM{mzOS=>
HuH-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISyTWkxNjQkgKOxNFAxyqCwTR?= M{fLPVczKGh? NXzkS2oxTUN3ME2yO{4{yrF3LkCgcm0> MmjwNVk6OTN7M{W=
HuH-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6wMlPjiJNzMECwxsBvVQ>? MV:3NkBp M1fRZ2VEPTB;Mz63xtExNjZibl2= MkH5NVk6OTN7M{W=
HuH-7 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjSZ|FYOC5|4pETNVAxOMLibl2= MmLTO|IhcA>? NHK4[IlGSzVyPU[uPOKyOC5|IH7N NH:3OVgyQTlzM{mzOS=>
HLE MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr2O2sxNjQkgKOxNFAxyqCwTR?= NXXBR3RUPzJiaB?= M3HrSmVEPTB;NEWuPeKyPi52IH7N NGXZV|kyQTlzM{mzOS=>
HLF MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[wMlPjiJNzMECwxsBvVQ>? MkjCO|IhcA>? NFm0[45GSzVyPUGyOk4yyrFzMj6yJI5O MmiyNVk6OTN7M{W=
PLC/PRF/5 M3TVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPJN25xOC5|4pETNVAxOMLibl2= MoLvO|IhcA>? Mn7hSWM2OD15Nj65xtE6Njlibl2= MoTnNVk6OTN7M{W=
SK-Hep1 NUPRV3ZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrJRpVsOC5|4pETNVAxOMLibl2= MliyO|IhcA>? M1z6dGVEPTB;MkGuPeKyOS5{IH7N M{Xo[FE6QTF|OUO1
Hep3B NYTDXopuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[5NE4{6oDVMUCwNOKhdk1? NIDpdFE4OiCq NWXXZZFJTUN3ME23MlbDuTFwMjDuUS=> MVKxPVkyOzl|NR?=
HepG2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLINE4{6oDVMUCwNOKhdk1? NEHKelU4OiCq NWrYdlZ2TUN3ME2xOE44yrFzLkegcm0> M3yycFE6QTF|OUO1
Ramos NF7Y[ZZCeG:ydH;zbZMhSXO|YYm= M3TWc|I2NzVyL{GwNEBvVQ>? Mlq2OFghcA>? MYrpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= MkDoNVk5OjNzNki=
Daudi  NUThNGtSSXCxcITvd4l{KEG|c3H5 MV[yOU82OC9zMECgcm0> MWi0PEBp MXzpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= NXnmem1mOTl6MkOxOlg>
BALM-14 NYTSTFlJSXCxcITvd4l{KEG|c3H5 MVqxNk42NzJ3L{WwJI5O NWq5NXdqPDhiaB?= M4\VXYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> MXOxPVgzOzF4OB?=
BALM-27 NEn4NHlCeG:ydH;zbZMhSXO|YYm= MVWxNk42NzJ3L{WwJI5O M{DYT|Q5KGh? NIG0NodqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> MUmxPVgzOzF4OB?=
NB4 NI\wbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXPO3kxNjBzL{CuNU8yKM7:TR?= NHW1VmY1QCCq NHfKbHZqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 NEfzU5UyQDN4N{S4OC=>

... Click to View More Cell Line Experimental Data

In vivo試験 Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM13 xenografts, confirmed by the observation of necrotic tissue with infiltration of phagocytic cells. [1] In addition, AZD1152 (10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, including colon, breast, and lung cancers, in a dose-dependent manner. [2]
臨床試験 A Phase I study to assess the safety and tolerability of AZD1152-HQPA in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML) has been completed.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1, and K562 cells
濃度 Dissolved in DMSO, final concentrations ~100 nM
反応時間 24 or 48 hours
実験の流れ Cells are exposed to various concentrations of AZD1152 for 24 or 48 hours. Cell proliferation is measured by 3H-thymidine uptake (isotope added 6 hours before harvest), and the concentration that induced 50% growth inhibition (IC50) is calculated from dose-response curves. Cell cycle analysis is performed by flow cytometry. Cell apoptosis is measured by annexin V–FITC apoptosis detection kit.

動物実験: [1]

動物モデル Female immune-deficient BALB/c nude mice subcutaneously injected with MOLM13 cells
製剤 Dissolved in 3M Tris, pH 9.0, at a concentration of 2.5 mg/mL
投薬量 5 or 25 mg/kg
投与方法 Intraperitoneal injection 4 times a week or every another day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Barasertib (AZD1152-HQPA) SDF
分子量 507.56
化学式

C26H30FN7O3

CAS No. 722544-51-6
保管 2年-20℃
6月-80℃in solvent
別名 INH 34
溶解度 (25°C) * In vitro DMSO 102 mg/mL (200.96 mM)
エタノール 3 mg/mL (5.91 mM)
<1 mg/mL (<1 mM)
In vivo 30% PEG 400/0.5% Tween 80/5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 2-(5-(7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-ylamino)-1H-pyrazol-3-yl)-N-(3-fluorophenyl)acetamide

カスタマーフィードバック (8)


Click to enlarge
Rating
Source Nature, 2014, 508(7494), 118-22. Barasertib (AZD1152-HQPA) purchased from Selleck
Method Long-term cell proliferation assays
Cell Lines A375-SOX10KD cells
Concentrations 0.5 uM
Incubation Time 4 weeks
Results Compared with controls, treatment of A375-SOX10KD cells with a combination of both vemurafenib and GDC0941 lead to proliferation arrest.

Click to enlarge
Rating
Source J Exp Med, 2014, 10.1084/jem.20141123. Barasertib (AZD1152-HQPA) purchased from Selleck
Method Giemsa staining
Cell Lines Primary MKPs
Concentrations
Incubation Time
Results Notably, Aurora B inhibitor (AZD-1152) treatment caused primary MKPs maturation and normal DNA ploidy.

Click to enlarge
Rating
Source Clin Cancer Res , 2010, 16, 4572-4582. Barasertib (AZD1152-HQPA) purchased from Selleck
Method alamarBlue assay
Cell Lines NB TICs
Concentrations
Incubation Time 72 h
Results Proliferation of NB TICs is reduced following inhibition of AURKB, showing low micromolar EC50 values (1.5-4.6 μmol/L). In contrast to this, SKPs were less sensitive to AZD1152, exhibiting higher EC50 values (12.4 μmol/L).

Click to enlarge
Rating
Source Oncogene, 2012, 31, 1217–1227. Barasertib (AZD1152-HQPA) purchased from Selleck
Method FACS
Cell Lines OVCAR10 cells
Concentrations
Incubation Time 3 h
Results Further, although a >4N hyperploid population was induced by treatment of cells with inhibitors selective for AURKA (MLN8257) or AURKB (AZD1152), only the combination of dasatinib with MLN8257 selectively reduced this population of cells.

Click to enlarge
Rating
Source Oncogene, 2014, 33, 3550-60. Barasertib (AZD1152-HQPA) purchased from Selleck
Method Western blot, time-lapse microscopy, flow cytometry
Cell Lines HeLa cells , HCT116 cells
Concentrations 6.25-50 nM
Incubation Time 2 h, 24 h, 48 h
Results Barasertib inhibits AURKB specifically and triggers mitotic slippage

Click to enlarge
Rating
Source J Biol Chem , 2011, 286, 2236-44. Barasertib (AZD1152-HQPA) purchased from Selleck
Method luciferase reporter assay, Western blotting, mass spectrometry analysis, kinase assay, Immunoprecipitation Assay
Cell Lines U2OS cells, H1299 cells
Concentrations 0-120 nM
Incubation Time 12 h/16 h
Results As shown in Fig. A, whereas wild-type Aurora B efficiently suppressed p53 in a luciferase reporter assay, a kinase-inactive Aurora B mutant (K106R) had a minimal effect on p53 transcriptional activity. In line with this, treatment of U2OS cells, but not H1299 cells, with the Aurora B-specific inhibitor AZD1152 markedly induced Bax expression (Fig. B). As shown in Fig. C, AZD1152 significantly induced Bax expression in the cells released from mitosis, suggesting that Aurora B is required for p53 suppression in G 1 to early S-phase. To determine whether Aurora B directly phosphorylates p53, we performed an in vitro kinase assay using Aurora B protein expressed in insect cells as the kinase source and GST-p53 purified from bacteria as the substrate and confirmed that Aurora B directly phosphorylates p53 (Fig. D).

Click to enlarge
Rating
Source J Pharmacol Exp Ther, 2012, 343(3), 617-27. Barasertib (AZD1152-HQPA) purchased from Selleck
Method ELISA/Kinase Assays
Cell Lines Mice-bearing tumors
Concentrations 25 mg/kg
Incubation Time 0-7 day
Results ABT-348 inhibited the VEGF response with a potency (ED 50 = 0.2 mg/kg i.v.) that is comparable with another potent anti-VEGF agent, ABT-869, which has intrinsic VEGFR2 potency similar to ABT-348 (IC 50 = 4 and 3 nM, respectively). On-target VEGF receptor inhibition was also implicated by the observation that administration of ABT-348 to tumor-bearing mice resulted in increased plasma levels of the proangiogenic PLGF (Fig. B). acute changes in the MRI signal were observed during treatment with ABT-348 (Fig. C). After a sharp decrease in Ktrans that was apparent within 24 h after the first treatment cycle of ABT-348, the MRI signal returned to pretreatment levels by 6 days when reassessed longitudinally, which was reflective of the Q7D-dosing sequence. (Fig. D) the reduction in Ktrans (75%) was similar in magnitude to that previously reported for the selective EGFR/PDGFR inhibitor.

Click to enlarge
Rating
Source Dr. Gao Zhang of University of Pennsylvania. Barasertib (AZD1152-HQPA) purchased from Selleck
Method Western blot
Cell Lines 1205Lu cells
Concentrations 50-500 nM, 2-8 μM
Incubation Time 48 h
Results AZD1152 treatment resulted in a reduction of Rb Ser780 phosphorylation at higher concentration.

文献中の引用 (23)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related オーロラ・キナーゼ 阻害剤

  • Ro-3306

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • CCG-1423

    CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.

  • ML141

    ML141 is a potent, selective and reversible non-competitive inhibitor of Rho family GTPase cdc42 with IC50 of 200 nM.

  • Salirasib

    Salirasib is a potent competitive prenylated protein methyltransferase (PPMTase) inhibitor with Ki of 2.6 μM, which inhibits Ras methylation. Phase 2.

  • Alisertib (MLN8237)

    Alisertib (MLN8237)は、1.2nMのIC50による選択的なオーロラA阻害剤です。

    Features:First orally available inhibitor of Aurora A.

  • VX-680 (Tozasertib, MK-0457)

    VX-680 (Tozasertib, MK-0457)は汎オーロラ・キナーゼ(AK)阻害剤、、オーロラA、オーロラBとオーロラCに作用すると、 Kiapp がそれぞれ 0.6 nM、18 nM 、 4.6 nMになる。

  • Danusertib (PHA-739358)

    Danusertib (PHA-739358)は ポ-ピラゾール分子が小さいauroraキナーゼとBcr-Ablキナーゼ阻害剤、auroraA, B, Cを作用すると、 IC50がそれぞれ 13 nM, 79 nM, 61 nMとなる.

  • ZM 447439

    ZM 447439は、オーロラ選択ATPです-競争的な阻害剤で、オーロラAキナーゼとオーロラBキナーゼに作用すると、IC50が それぞれ 110 nM と 130 nM,になる。

    Features:An Aurora selective ATP-competitive inhibitor.

  • MLN8054

    MLN8054は、4nMのIC50によるオーロラAキナーゼの強力で選択的な阻害剤です。

最近チェックしたアイテム

Tags: Barasertib (AZD1152-HQPA)を買う | Barasertib (AZD1152-HQPA)供給者 | Barasertib (AZD1152-HQPA)を購入する | Barasertib (AZD1152-HQPA)費用 | Barasertib (AZD1152-HQPA)生産者 | オーダーBarasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ